Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly. See the outlook here.
Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer s disease dementia. This was an open-label safety study with exploratory. | January 25, 2023
Cassava Sciences (SAVA) Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Bringing Aduhelm—and Antibodies to Come—Into Practice alzforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzforum.org Daily Mail and Mail on Sunday newspapers.